Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 12;21(2):13.
doi: 10.1007/s11906-019-0921-3.

Personalized Medicine and the Treatment of Hypertension

Affiliations
Review

Personalized Medicine and the Treatment of Hypertension

Sarah Melville et al. Curr Hypertens Rep. .

Abstract

Purpose of review: The purpose of this review is to discuss the implications of personalized medicine for the treatment of hypertension, including resistant hypertension.

Recent findings: We suggest a framework for the personalized treatment of hypertension based on the concept of a trade-off between simplicity and personalization. This framework is based on treatment strategies classified as low, medium, or high information burden personalization approaches. The extent to which a higher information burden is justified depends on the clinical scenario, particularly the ease with which the blood pressure can be controlled. A one-size-fits-many treatment strategy for hypertension is efficacious for most people; however, a more personalized approach could be useful in patients with subtypes of hypertension that do not respond as expected to treatment. Clinicians seeing patients with unusual hypertension phenotypes should be familiar with emerging trends in personalized treatment of hypertension.

Keywords: Blood pressure; Hypertension; Personalized medicine; Population health; Primary aldosteronism; Resistant hypertension.

PubMed Disclaimer

Figures

Figure
Figure
A) Low information burden personalized medicine approaches can be adequate for treatment efficacy (e.g. one-size-fits-many). In some cases, however, the low information burden approaches to treatment do not provide effective results, so B) reasonable higher information burden personalized medicine approaches should be considered.

References

    1. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1659–724. doi: 10.1016/s0140-6736(16)31679-8. - DOI - PMC - PubMed
    1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018;392(10159):2052–90. doi: 10.1016/s0140-6736(18)31694-5. - DOI - PMC - PubMed
    1. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017;389(10064):37–55. doi: 10.1016/s0140-6736(16)31919-5. - DOI - PMC - PubMed
    1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA 2017;317(2):165–82. doi: 10.1001/jama.2016.19043. - DOI - PubMed
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):1269–324. doi: 10.1161/hyp.0000000000000066. - DOI - PubMed

Publication types

Substances